{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:59:57Z","timestamp":1789207197313,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2001,2,1]],"date-time":"2001-02-01T00:00:00Z","timestamp":980985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":6900,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2001,2]]},"DOI":"10.1023\/a:1008378412533","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T09:41:38Z","timestamp":1040550098000},"page":"221-226","source":"Crossref","is-referenced-by-count":50,"title":["CEA and CA19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA)"],"prefix":"10.1016","volume":"12","author":[{"given":"B.","family":"Hanke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Riedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lampert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Happich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Martus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Parsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Himmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Hohenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.G.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Wein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1023\/A:1008378412533_bb0010","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1200\/JCO.1998.16.2.418","article-title":"Effective biomodulation by leukovorin of high-dose infusion fluorouracil given as weekly 24-hour infusion: Results of a randomized trial in patients with advanced colorectal cancer","volume":"16","author":"K\u00f6hne","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008378412533_bb0015","first-page":"1162","article-title":"High efficacy of first-line 5-fluorouracil 24-hour infusion and folinic acid chemotherapy in patients with metastatic colorectal cancer","volume":"17","author":"Riedel","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1008378412533_bb0020","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/0959-8049(94)90314-X","article-title":"Weekly therapy with folinic acid and high-dose 5-fluorouracil 24-hour infusion in previously untreated patients with metastatic colorectal carcinoma","volume":"30","author":"Weh","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1023\/A:1008378412533_bb0025","first-page":"403","article-title":"A randomized phase III study comparing weekly folinic acid (FA) and high-dose 5-fluorouracil (5-FU) with monthly 5-FU\/FA (days 1\u20135) in untreated patients with metastatic colorectal cancer","volume":"21","author":"Weh","year":"1998","journal-title":"Onkologie"},{"key":"10.1023\/A:1008378412533_bb0030","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-2007-1023957","article-title":"Verbesserungen der palliativen Behandlng des kolorektalen Karzinoms","volume":"125","author":"Wein","year":"2000","journal-title":"Dtsch Med Wschr"},{"key":"10.1023\/A:1008378412533_bb0035","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0092-8674(89)90970-7","article-title":"Carcinoembryonic antigen: A human tumor marker, functions as an intercellular adhesion molecule","volume":"57","author":"Benchimol","year":"1989","journal-title":"Cell"},{"key":"10.1023\/A:1008378412533_bb0040","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/1097-0142(197809)42:3+<1428::AID-CNCR2820420808>3.0.CO;2-H","article-title":"Carcinoembryonic antigen (CEA) as a monitor of chemotherapy in dissimulated colorectal cancer","volume":"42","author":"Mayer","year":"1978","journal-title":"Cancer"},{"issue":"10","key":"10.1023\/A:1008378412533_bb0045","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/bjc.1998.682","article-title":"Preoperative carcinoembryonic antigen is related to tumour stage and long-term survival in colorectal cancer","volume":"78","author":"Chapman","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1023\/A:1008378412533_bb0050","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/1097-0142(197809)42:3+<1439::AID-CNCR2820420811>3.0.CO;2-X","article-title":"Long-term follow-up of colorectal carcinoma patients by repeated CEA radioimmunoassay","volume":"42","author":"Mach","year":"1978","journal-title":"Cancer"},{"key":"10.1023\/A:1008378412533_bb0055","doi-asserted-by":"crossref","first-page":"66","DOI":"10.7326\/0003-4819-104-1-66","article-title":"Carcinoembryonic antigen","volume":"104","author":"Fletcher","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1023\/A:1008378412533_bb0060","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/bjc.1994.343","article-title":"The role of CA-242 and CEA in surveillance following curative resection for colorectal cancer","volume":"70","author":"Hall","year":"1994","journal-title":"Br J Cancer"},{"key":"10.1023\/A:1008378412533_bb0065","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/bjc.1993.208","article-title":"The use of tumor markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer","volume":"67","author":"Ward","year":"1993","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1023\/A:1008378412533_bb0070","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/(SICI)1097-0142(19990215)85:4<786::AID-CNCR5>3.0.CO;2-9","article-title":"A multicenter phase II trial of weekly irinotecan (CPT-II) in patients with previously treated colorectal cancer","volume":"85","author":"Rothenberg","year":"1999","journal-title":"Cancer"},{"key":"10.1023\/A:1008378412533_bb0075","first-page":"1145","article-title":"Evaluation of carcinoembryonic antigen (CEA) levels during CPT-II treatment of patients with previously treated colorectal cancer","volume":"17","author":"Miller","year":"1998","journal-title":"Proc Am Soc Oncol"},{"key":"10.1023\/A:1008378412533_bb0080","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00000658-197701000-00004","article-title":"CEA monitoring of palliative treatment for colorectal carcinoma","volume":"185","author":"Herrera","year":"1977","journal-title":"Ann Surg"},{"issue":"1","key":"10.1023\/A:1008378412533_bb0085","first-page":"45","article-title":"Value of CEA determination in follow-up of patients with liver metastasis of colorectal cancers with loco-regional chemotherapy","volume":"116","author":"Schimpfle","year":"1991","journal-title":"Zentralbl Chir"},{"key":"10.1023\/A:1008378412533_bb0090","first-page":"5489","article-title":"Identification of gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin","volume":"43","author":"Magnani","year":"1983","journal-title":"Cancer Res"},{"key":"10.1023\/A:1008378412533_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000217867","article-title":"Use of CA 19-9 in the early detection of recurrences in colorectal cancer: Comparison with CEA","volume":"15","author":"Filella","year":"1994","journal-title":"Tumor Biol"},{"key":"10.1023\/A:1008378412533_bb0100","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/jso.2930490204","article-title":"19-9 as the most significant prognostic factor in advanced coloreclal cancer","volume":"49","author":"Kouri","year":"1992","journal-title":"J Surg Oncol"},{"issue":"2","key":"10.1023\/A:1008378412533_bb0105","first-page":"793","article-title":"update of recommendations for the use of tumor markers in breast and colorectal cancer","volume":"16","author":"Special Article","year":"1997","journal-title":"J Clin Oncol 1998"},{"issue":"2","key":"10.1023\/A:1008378412533_bb0110","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/172460089300800204","article-title":"Carcinoembryonic antigen (CEA), alpha-fetoprotein. CA 19-9 and CA 125 in advanced colorectal cancer (ACC)","volume":"8","author":"Tsavaris","year":"1993","journal-title":"Int J Biol Markers"},{"key":"10.1023\/A:1008378412533_bb0115","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0959-8049(96)00370-X","article-title":"Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continous infusion in pretreated metastatic coloreclal cancer","volume":"33","author":"De Gramont","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1023\/A:1008378412533_bb0120","first-page":"937","article-title":"Phase III study of irinotecan as second line chemotherapy in metastatic colorectal cancer","volume":"18","author":"Hoffken","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1008378412533_bb0125","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0959-8049(99)80694-7","article-title":"Phase II-study of 24-hour infusion with 5-fluorouracil (5-FU) and simultaneous sodium folinic acid in the first-line treatment of advanced colorectal cancer: Interim analysis","volume":"35","author":"Hofheinz","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1023\/A:1008378412533_bb0130","series-title":"Practical Statistics for Medical Research","author":"Altman","year":"1991"},{"key":"10.1023\/A:1008378412533_bb0135","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1126\/science.3287615","article-title":"Measurung the accuracy of diagnostic systems","volume":"240","author":"Swets","year":"1988","journal-title":"Science"},{"issue":"2","key":"10.1023\/A:1008378412533_bb0140","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/172460088800300205","article-title":"The clinical relevance of tumor marker CEA. CA 19-9 in regional chemotherapy of hepatic metastases of colorectal carcinoma","volume":"3","author":"Safi","year":"1988","journal-title":"Int J Biol Markers"},{"key":"10.1023\/A:1008378412533_bb0145","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(00)02528-9","article-title":"Relation between tumor response to first-line chemotherapy and survival in advanced colorectal cancer: A meta-analysis","volume":"356","author":"Buyse","year":"2000","journal-title":"Lancet"},{"key":"10.1023\/A:1008378412533_bb0150","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1136\/gut.25.6.682","article-title":"Prospective randomised trial of early cytotoxic therapy for recurrent colorectal carcinoma detected by serum CEA","volume":"25","author":"Hine","year":"1984","journal-title":"Gut"},{"key":"10.1023\/A:1008378412533_bb0155","first-page":"1279","article-title":"Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer","volume":"4","author":"Kumar","year":"1998","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1023\/A:1008378412533_bb0160","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/bjc.1998.514","article-title":"Serum hepatocyte growth factor as an index of disease status of patients with colorectal carcinoma","volume":"78","author":"Fukuura","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1023\/A:1008378412533_bb0165","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/(SICI)1097-0215(19980220)79:1<76::AID-IJC15>3.0.CO;2-F","article-title":"Over-expression of ICAM-I, VCAM-I and ELAM-I might influence tumor progression in colorectal cancer","volume":"79","author":"Maurer","year":"1998","journal-title":"Int J Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341947289X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341947289X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/12\/2\/221\/19479229\/12-2-221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T01:57:02Z","timestamp":1582163822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341947289X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,2]]}},"alternative-id":["S092375341947289X"],"URL":"https:\/\/doi.org\/10.1023\/a:1008378412533","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2001,2]]}}}